Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 20/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 20/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13866645 | 1.00 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13866647 | 0.92 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13866649 | 0.92 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13866707 | 0.91 | DRD2 (0.84) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13875199 | 0.91 | DRD2 (0.84) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13866674 | 0.90 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13866681 | 0.90 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13866673 | 0.90 | DRD2 (0.82) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL3863575 | 0.90 | ADRA1D (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13866669 | 0.90 | ADRA1D (1.00) | DRD2ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517885-B2 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| US-7517885-B2 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| US-20070123542-A1 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | CHIU GEORGE | 2007-05-31 | — | — | US | disclosed |
| US-20070123542-A1 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | CHIU GEORGE | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123542-A1 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | ADRA1D, ADRA1A, ADRB1 | DRD2 662/4885ADRA1D 1/4885ADRA1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.